Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

There is a lack of new antibiotics to combat drug-resistant bacterial infections that
increasingly threaten global health. The current pipeline of clinical-stage antimicrobials is …

Small molecules with antitubercular activity containing the pyrimidine motif in their structure
have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) is a critical flavoenzyme in
Mycobacterium tuberculosis, catalyzing a vital step in the production of lipoarabinomannan …

ABSTRACT BTZ-043, a suicide inhibitor of the Mycobacterium tuberculosis cell wall
synthesis decaprenylphosphoryl-beta-d-ribose 2′ epimerase, is under clinical …

Mycobacterium tuberculosis possesses a dynamic cell envelope, which consists of a
peptidoglycan layer, a mycolic acid layer, and an arabinogalactan polysaccharide. This …

Abstract Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1) inhibitors are an innovative
and futuristic orally active group of antituberculosis agents. A few DprE1 inhibitors are in the …

Tuberculosis (TB) is the leading cause of death from any bacterial infection, causing 1.5
million deaths worldwide each year. Due to the emergence of drug-resistant strains of …